Tg Therapeutics, Inc.NASDAQ: TGTX

TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis

· Issued by Tg Therapeutics, Inc.
Watch Tg Therapeutics explain itTG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call · Replay · Aug 3

Both studies met their primary endpoint of significantly reducing annualized relapse rate (ARR) (p